Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $18.75.

Several brokerages recently commented on KLRS. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research report on Wednesday, May 13th. Weiss Ratings cut shares of Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, June 14th. TD Cowen started coverage on Kalaris Therapeutics in a research report on Monday, June 15th. They issued a “buy” rating on the stock. Finally, Citizens Jmp reduced their target price on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th.

Hedge Funds Weigh In On Kalaris Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Pale Fire Capital SE purchased a new stake in shares of Kalaris Therapeutics during the 2nd quarter worth about $161,000. Velan Capital Investment Management LP raised its holdings in Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after buying an additional 7,000 shares during the period. Sigma Planning Corp acquired a new position in Kalaris Therapeutics during the second quarter valued at approximately $41,000. Stonepine Capital Management LLC acquired a new position in Kalaris Therapeutics during the second quarter valued at approximately $122,597. Finally, ADAR1 Capital Management LLC purchased a new stake in Kalaris Therapeutics during the second quarter worth approximately $407,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Kalaris Therapeutics Stock Performance

Shares of NASDAQ:KLRS opened at $4.03 on Monday. The firm has a market cap of $95.95 million, a price-to-earnings ratio of -2.00 and a beta of 0.20. The stock’s 50-day moving average price is $4.17 and its two-hundred day moving average price is $5.76. Kalaris Therapeutics has a 12-month low of $3.03 and a 12-month high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. As a group, research analysts forecast that Kalaris Therapeutics will post -1.99 earnings per share for the current fiscal year.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.